Ambitious companies serving the global research science market need state of the art solutions to be able to generate success and help establish a critical mass. The current amsbio
portfolio is a testimony to this. Specializing in Genomics, Proteomics, Cell Culture and Stem Cell Sciences, AMSBIO continues to offer a wide range of solutions from leading manufacturing partners and academic
technology transfer departments. Key areas include
cell migration, invasion, adhesion and
proliferation where a number of platforms suitable for high content analysis are available. Growing cells in 3D is
physiologically relevant and the most innovative set of products and technology currently commercially available for 3-D cell culture has been put together under the AMSBIO umbrella. These products are being used in key regenerative medicine therapy and cancer research as well as offering alternatives to the use of animals in biomedical research.
AMSBIO offers one of the biggest range of
tissue products from a single source.
protein and tissue sections and arrays are available from diseased and normal sources and multiple donor provision and prospective collection is also possible.
During 2009 3i sold its investment in AMSBIO to Alex Sim, the group’s interests are now represented in AMSBIO holdings. AMSBIO LLC was formed in 2011 to take control of Southern California based laboratory and physical distribution assets.